Worsening of Huntington disease phenotype in CB1 receptor knockout mice

被引:51
作者
Mievis, Stephane [2 ]
Blum, David [1 ,3 ,4 ]
Ledent, Catherine [2 ]
机构
[1] Jean Pierre Aubert Res Ctr, INSERM, U837, F-59045 Lille, France
[2] Univ Libre Bruxelles, IRIBHM, Brussels, Belgium
[3] Univ Lille Nord France, UDSL, IMPRT, Lille, France
[4] CHRU Lille, Lille, France
关键词
CB1; receptor; Huntington's disease; N171-82Q; Transgenic model; 3-nitropropionic acid; Striatum; ADENOSINE A(2A) RECEPTORS; MESSENGER-RNA LEVELS; 3-NITROPROPIONIC ACID; CANNABINOID RECEPTORS; NEUROTROPHIC FACTOR; BASAL GANGLIA; NEURODEGENERATIVE DISEASES; STRIATAL DEGENERATION; CONSTITUTIVE ACTIVITY; MOTOR DYSFUNCTION;
D O I
10.1016/j.nbd.2011.03.006
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Huntington's disease (HD) is a progressive neurodegenerative genetic disorder which leads to motor, cognitive and psychiatric disturbances. The primary neuropathological hallmark is atrophy of the striatum. Cannabinoid CB1 receptors (CB1Rs) are particularly enriched in the striatum and previous works indicate their early loss of expression in HD, even before symptom occurrence. However, pathophysiological significance of this loss of expression remains unclear. In addition, whether specific modulation of CB1R is able to mitigate striatal neuron fate in HD remains currently controversial. In order to gain further insights on the potential role of CB1R in HD physiopathology, we evaluated the pathophysiological consequences of a genetic deletion of CB1R in the N171-82Q transgenic model and following 3-nitropropionic (3NP) intoxication. Taken together our data demonstrate that CB1R knockout (1) worsens motor performances in N171-82Q mice and (2) increases mouse susceptibility to 3NP. These results suggest that functional changes in CB1R may contribute to the physiopathological development of HD. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:524 / 529
页数:6
相关论文
共 44 条
[1]
Minocycline in phenotypic models of Huntington's disease [J].
Bantubungi, K ;
Jacquard, C ;
Greco, A ;
Pintor, A ;
Chtarto, A ;
Tai, K ;
Galas, MC ;
Tenenbaum, L ;
Déglon, N ;
Popoli, P ;
Minghetti, L ;
Brouillet, E ;
Brotchi, J ;
Levivier, M ;
Scbiffmann, SN ;
Blum, D .
NEUROBIOLOGY OF DISEASE, 2005, 18 (01) :206-217
[2]
Bantubungi K, 2007, Rev Med Brux, V28, P487
[3]
Bantubungi K, 2007, Rev Med Brux, V28, P413
[4]
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease [J].
Blazquez, Cristina ;
Chiarlone, Anna ;
Sagredo, Onintza ;
Aguado, Tania ;
Ruth Pazos, M. ;
Resel, Eva ;
Palazuelos, Javier ;
Julien, Boris ;
Salazar, Maria ;
Boerner, Christine ;
Benito, Cristina ;
Carrasco, Carolina ;
Diez-Zaera, Maria ;
Paoletti, Paola ;
Diaz-Hernandez, Miguel ;
Ruiz, Carolina ;
Sendtner, Michael ;
Lucas, Jose J. ;
de Yebenes, Justo G. ;
Marsicano, Giovanni ;
Monory, Krisztina ;
Lutz, Beat ;
Romero, Julian ;
Alberch, Jordi ;
Gines, Silvia ;
Kraus, Juergen ;
Fernandez-Ruiz, Javier ;
Galve-Roperh, Ismael ;
Guzman, Manuel .
BRAIN, 2011, 134 :119-136
[5]
Blum D, 2003, J NEUROSCI, V23, P5361
[6]
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease [J].
Blum, D ;
Galas, MC ;
Gall, D ;
Cuvelier, L ;
Schiffmann, SN .
NEUROBIOLOGY OF DISEASE, 2002, 10 (03) :410-426
[7]
Blum D, 2002, J NEUROSCI, V22, P9122
[8]
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase [J].
Borrell-Pagès, M ;
Canals, JM ;
Cordelières, FP ;
Parker, JA ;
Pineda, JR ;
Grange, G ;
Bryson, EA ;
Guillermier, M ;
Hirsch, E ;
Hantraye, P ;
Cheetham, ME ;
Néri, C ;
Alberch, J ;
Brouillet, E ;
Saudou, F ;
Humbert, S .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1410-1424
[9]
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease [J].
Brouillet, E ;
Jacquard, C ;
Bizat, N ;
Blum, D .
JOURNAL OF NEUROCHEMISTRY, 2005, 95 (06) :1521-1540
[10]
Brouillet E, 1998, J NEUROCHEM, V70, P794